FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:452-458 August 12, 1993 Number 7 Next

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The relative efficacies of various antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias are not well known. This study examined the effectiveness of imipramine, mexiletine, pirmenol, procainamide, propafenone, quinidine, and sotalol in patients with ventricular tachyarrhythmias who were enrolled in the Electrophysiologic Study versus Electrocardiographic Monitoring trial.

Methods Patients were randomly assigned to undergo serial testing of the efficacy of the seven antiarrhythmic drugs by one of two strategies: electrophysiologic study or Holter monitoring together with exercise testing. The seven drugs were then tested for efficacy in random order in patients who were eligible to receive them. The frequencies of predictions of drug efficacy and of adverse drug effects during the initial drug titration were tabulated for all 486 randomized subjects. Patients received long-term treatment with the first antiarrhythmic drug that was predicted to be effective on the basis of drug testing. Recurrences of arrhythmia, deaths, and adverse drug effects during long-term follow-up were recorded for the 296 patients in whom an antiarrhythmic drug was predicted to be effective.

Results In the electrophysiologic-study group, the percentage of patients who had predictions of drug efficacy was higher with sotalol (35 percent) than with the other drugs (16 percent, P<0.001). There was no significant difference among the drugs in the Holter-monitoring group. The percentage of patients with adverse drug effects was lowest among those receiving sotalol. The actuarial probability of a recurrence of arrhythmia after a prediction of drug efficacy by either strategy was significantly lower for patients treated with sotalol than for patients treated with the other drugs (risk ratio, 0.43; 95 percent confidence interval, 0.29 to 0.62; P<0.001). With sotalol, as compared with the other drugs combined, there were lower risks of death from any cause (risk ratio, 0.50; 95 percent confidence interval, 0.30 to 0.80; P = 0.004), death from cardiac causes (0.50; P = 0.02), and death from arrhythmia (0.50; P = 0.04). The cumulative percentage of patients in whom a drug was predicted to be effective and in whom it remained effective and tolerated was higher for sotalol than for the other drugs (P<0.001).

Conclusions Sotalol was more effective than the other six antiarrhythmic drugs in preventing death and recurrences of arrhythmia. In patients similar to those in this study, if antiarrhythmic-drug therapy is to be used to prevent recurrences of ventricular tachyarrhythmias, treatment with sotalol and assessment of its potential efficacy by Holter monitoring are a reasonable initial strategy.

Source Information

The study investigators are listed in the Appendix of the preceding article.

From the Cardiology Division, University of Utah Medical Center, 50 N. Medical Dr., Salt Lake City, UT 84132, where reprint requests should be addressed to Dr. Mason.

Full Text of this Article

This article has been cited by other articles:

• Chan, P. S., Hayward, R. A. (2005). Mortality Reduction by Implantable Cardioverter-Defibrillators in High-Risk Patients With Heart Failure, Ischemic Heart Disease, and New-Onset Ventricular Arrhythmia: An Effectiveness Study. J Am Coll Cardiol 45: 1474-1481 [Abstract] [Full Text]  
• Thompson, A., Balser, J. R. (2004). Perioperative cardiac arrhythmias. Br J Anaesth 93: 86-94 [Abstract] [Full Text]  
• Yeung-Lai-Wah, J. A., Qi, A., McNeill, E., Abel, J. G., Tung, S., Humphries, K. H., Kerr, C. R. (2004). New-onset sustained ventricular tachycardia and fibrillation early after cardiac operations. Ann. Thorac. Surg. 77: 2083-2088 [Abstract] [Full Text]  
• Calvert, C. A., Brown, J. (2004). Influence of Antiarrhythmia Therapy on Survival Times of 19 Clinically Healthy Doberman Pinschers With Dilated Cardiomyopathy That Experienced Syncope, Ventricular Tachycardia, and Sudden Death (1985-1998). Journal of the American Animal Hospital Association 40: 24-28 [Abstract] [Full Text]  
• Anstadt, M. P., Lowe, J. E. (2003). Cardiopulmonary Resuscitation. Card Surg Adult 2: 471-494 [Full Text]  
• Singh, B. N. (2002). Atrial Fibrillation Following Investigation of Rhythm Management: AFFIRM Trial Outcomes. What Might Be Their Implications for Arrhythmia Control?. J CARDIOVASC PHARMACOL THER 7: 131-133  
• Schlapfer, J.u., Rapp, F., Kappenberger, L., Fromer, M. (2002). Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: Results of long-term follow-up. J Am Coll Cardiol 39: 1813-1819 [Abstract] [Full Text]  
• Saoudi, N., Rinaldi, J.P., Yaici, K., Bergonzi, M. (2001). Dofetilide: what role in the treatment of ventricular tachyarrhythmias?. Eur Heart J 22: 2141-2143  
• Boriani, G., Lubinski, A., Capucci, A., Niederle, P., Kornacewicz-Jack, Z., Wnuk-Wojnar, A.M., Borggrefe, M., Brachmann, J., Biffi, M., Butrous, G.S., on behalf of Ventricular Arrhythmias Dofetilide In, (2001). A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur Heart J 22: 2180-2191 [Abstract]  
• Klingenheben, T., Gronefeld, G., Li, Y.-G., Hohnloser, S. H. (2001). Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans: Results of a prospective, double-blind, randomized study. J Am Coll Cardiol 38: 2013-2019 [Abstract] [Full Text]  
• Priori, S.G., Aliot, E., Blomstrom-Lundqvist, C., Bossaert, L., Breithardt, G., Brugada, P., Camm, A.J., Cappato, R., Cobbe, S.M., Di Mario, C., Maron, B.J., McKenna, W.J., Pedersen, A.K., Ravens, U., Schwartz, P.J., Trusz-Gluza, M., Vardas, P., Wellens, H.J.J., Zipes, D.P. (2001). Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 22: 1374-1450  
• Mason, J. W. (2001). Mindfully mining MUSTT. J Am Coll Cardiol 38: 352-354 [Full Text]  
• Connelly, D. T (2001). ELECTROPHYSIOLOGY: Implantable cardioverter-defibrillators. Heart 86: 221-226 [Full Text]  
• Singh, B. N., Sarma, J. S. M. (2001). Mechanisms of Action of Antiarrhythmic Drugs Relative to the Origin and Perpetuation of Cardiac Arrhythmias. J CARDIOVASC PHARMACOL THER 6: 69-87  
• Kuck, K.-H., Cappato, R., Siebels, J., Ruppel, R. (2000). Randomized Comparison of Antiarrhythmic Drug Therapy With Implantable Defibrillators in Patients Resuscitated From Cardiac Arrest : The Cardiac Arrest Study Hamburg (CASH). Circulation 102: 748-754 [Abstract] [Full Text]  
• Oudijk, M. A., Michon, M. M., Kleinman, C. S., Kapusta, L., Stoutenbeek, P., Visser, G. H. A., Meijboom, E. J. (2000). Sotalol in the Treatment of Fetal Dysrhythmias. Circulation 101: 2721-2726 [Abstract] [Full Text]  
• Reiffel, J. A. (2000). The Importance of Considering Trial Design When Interpreting Clinical Trial Results. J CARDIOVASC PHARMACOL THER 5: 17-25 [Abstract]  
• Welch, P. J., Page, R. L., Hamdan, M. H. (1999). Management of ventricular arrhythmias: A trial-based approach. J Am Coll Cardiol 34: 621-630 [Abstract] [Full Text]  
• Goldberger, J. J. (1999). Treatment and Prevention of Sudden Cardiac Death: Effect of Recent Clinical Trials. Arch Intern Med 159: 1281-1287 [Abstract] [Full Text]  
• Pacifico, A., Hohnloser, S. H., Williams, J. H., Tao, B., Saksena, S., Henry, P. D., Prystowsky, E. N., The d,l-Sotalol Implantable Cardioverter-Defibrill, (1999). Prevention of Implantable-Defibrillator Shocks by Treatment with Sotalol. NEJM 340: 1855-1862 [Abstract] [Full Text]  
• Mewis, C., Kuhlkamp, V., Mermi, J., Bosch, R. F., Seipel, L. (1999). Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias. J Am Coll Cardiol 33: 1989-1995 [Abstract] [Full Text]  
• Anderson, J. L., Hallstrom, A. P., Epstein, A. E., Pinski, S. L., Rosenberg, Y., Nora, M. O., Chilson, D., Cannom, D. S., Moore, R. (1999). Design and Results of the Antiarrhythmics vs Implantable Defibrillators (AVID) Registry. Circulation 99: 1692-1699 [Abstract] [Full Text]  
• Kovoor, P., Eipper, V., Byth, K., Cooper, M.J., Uther, J.B., Ross, D.L. (1999). Comparison of sotalol with amiodarone for long-term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease. Eur Heart J 20: 364-374 [Abstract]  
• Cannom, D. S., Prystowsky, E. N. (1999). Management of Ventricular Arrhythmias: Detection, Drugs, and Devices. JAMA 281: 172-179 [Abstract] [Full Text]  
• Kuhlkamp, V., Mewis, C., Mermi, J., Bosch, R. F., Seipel, L. (1999). Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol 33: 46-52 [Abstract] [Full Text]  
• Singh, B. N. (1999). Review : Sotalol: Current Status and Expanding Indications. J CARDIOVASC PHARMACOL THER 4: 49-65 [Abstract]  
• Ruppel, R., Schluter, C. A., Boczor, S., Meinertz, T., Schluter, M., Kuck, K.-H., Cappato, R. (1998). Ventricular tachycardia during follow-up in patients resuscitated from ventricular fibrillation: experience from stored electrograms of implantable cardioverter-defibrillators. J Am Coll Cardiol 32: 1724-1730 [Abstract] [Full Text]  
• Adamson, P. B., Vanoli, E., Hull, S. S., Foreman, R. D., Schwartz, P. J. (1998). Antifibrillatory efficacy of ersentilide, a novel {beta}-adrenergic and Ikr blocker, in conscious dogs with a healed myocardial infarction. Cardiovasc Res 40: 56-63 [Abstract] [Full Text]  
• Causer, J. P, Connelly, D. T (1998). Implantable defibrillators for life threatening ventricular arrhythmias. BMJ 317: 762-763 [Full Text]  
• Mushlin, A. I., Hall, W. J., Zwanziger, J., Gajary, E., Andrews, M., Marron, R., Zou, K. H., Moss, A. J. (1998). The Cost-effectiveness of Automatic Implantable Cardiac Defibrillators: : Results From MADIT. Circulation 97: 2129-2135 [Abstract] [Full Text]  
• Sen, L., Cui, G., Sakaguchi, Y., Singh, B. N. (1998). Electrophysiological Effects of MS-551, a New Class III Agent: Comparison with dl-Sotalol in Dogs. J. Pharmacol. Exp. Ther. 285: 687-694 [Abstract] [Full Text]  
• Lowe, M D, Stone, D L, Grace, A A (1998). Sotalol associated polymorphic ventricular tachycardia and coronary spasm. Heart 79: 518-520 [Abstract] [Full Text]  
• Baskin, E. P., Lynch Jr., J. J. (1998). Differential Atrial versus Ventricular Activities of Class III Potassium Channel Blockers. J. Pharmacol. Exp. Ther. 285: 135-142 [Abstract] [Full Text]  
• Grace, A. A., Camm, A. J. (1998). Quinidine. NEJM 338: 35-45 [Full Text]  
• Sharma, P. P., Ott, P., Hartz, V., Mason, J. W., Marcus, F. I. (1998). Risk Factors for Tachycardia Events Caused by Antiarrhythmic Drugs: Experience From the ESVEM Trial. J CARDIOVASC PHARMACOL THER 3: 269-274 [Abstract]  
• The Antiarrhythmics versus Implantable Defibrillat, (1997). A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular Arrhythmias. NEJM 337: 1576-1584 [Abstract] [Full Text]  
• Caruso, A. C., Marcus, F. I., Hahn, E. A., Hartz, V. L., Mason, J. W. (1997). Predictors of Arrhythmic Death and Cardiac Arrest in the ESVEM Trial. Circulation 96: 1888-1892 [Abstract] [Full Text]  
• Singh, B. N. (1997). Class III Antiarrhythmic Drugs: Simple versus Complex Molecules for Controlling Cardiac Arrhythmias. J CARDIOVASC PHARMACOL THER 2: 1-5  
• Moss, A. J., Hall, W. J., Cannom, D. S., Daubert, J. P., Higgins, S. L., Klein, H., Levine, J. H., Saksena, S., Waldo, A. L., Wilber, D., Brown, M. W., Heo, M., The Multicenter Automatic Defibrillator Implantati, (1996). Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular Arrhythmia. NEJM 335: 1933-1940 [Abstract] [Full Text]  
• Lehmann, M. H., Hardy, S., Archibald, D., Quart, B., MacNeil, D. J. (1996). Sex Difference in Risk of Torsade de Pointes With d,l-Sotalol. Circulation 94: 2535-2541 [Abstract] [Full Text]  
• Bocker, D., Haverkamp, W., Block, M., Borggrefe, M., Hammel, D., Breithardt, G. (1996). Comparison of d,l-Sotalol and Implantable Defibrillators for Treatment of Sustained Ventricular Tachycardia or Fibrillation in Patients With Coronary Artery Disease. Circulation 94: 151-157 [Abstract] [Full Text]  
• Singh, B. N. (1996). Antiarrhythmic Therapy of Ventricular Arrhythmias: The Contemporary Dilemma. J CARDIOVASC PHARMACOL THER 1: 3-7  
• Sakai, F., Kawano, S., Hiraoka, M. (1996). Electrophysiologic Effects of Beta-blocking Agent, Tilisolol; on Isolated Guinea Pig Ventricular Myocytes. J CARDIOVASC PHARMACOL THER 1: 41-48 [Abstract]  
• Reiffel, J. A. (1996). Data-driven Decisions: The Importance of Clinical Trials in Arrhythmia Management. J CARDIOVASC PHARMACOL THER 1: 79-88 [Abstract]  
• Hohnloser, S. H., Meinertz, T., Stubbs, P., Crijns, H. J.G.M., Blanc, J.-J., Rizzon, P., Cheuvart, B. (1995). Efficacy and Safety of d-Sotalol, a Pure Class III Antiarrhythmic Compound, in Patients With Symptomatic Complex Ventricular Ectopy : Results of a Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Finding Study. Circulation 92: 1517-1525 [Abstract] [Full Text]  
• Gettes, L. S. (1995). ESVEM and the Hazards of Clinical Trials. Circulation 91: 1908-1909 [Full Text]  
• Reiter, M. J., Mann, D. E., Reiffel, J. E., Hahn, E., Hartz, V. (1995). Significance and Incidence of Concordance of Drug Efficacy Predictions by Holter Monitoring and Electrophysiological Study in the ESVEM Trial. Circulation 91: 1988-1995 [Abstract] [Full Text]  
• Omoigui, N. A., Marcus, F. I., Mason, J. W., Hahn, E. A., Hartz, V. L., Hlatky, M. A. (1995). Cost of Initial Therapy in the Electrophysiological Study Versus ECG Monitoring Trial (ESVEM). Circulation 91: 1070-1076 [Abstract] [Full Text]  
• Groh, W. J., Gibson, K. J., McAnulty, J. H., Maylie, J. G. (1995). ß-Adrenergic Blocking Property of dl-Sotalol Maintains Class III Efficacy in Guinea Pig Ventricular Muscle After Isoproterenol. Circulation 91: 262-264 [Abstract] [Full Text]  
• McMurray, J., Rankin, A. (1994). Recent Advances: Cardiology II: Treatment of heart failure and atrial fibrillation and arrhythmias. BMJ 309: 1631-1635 [Full Text]  
• Roden, D. M. (1994). Risks and Benefits of Antiarrhythmic Therapy. NEJM 331: 785-791 [Full Text]  
• Hohnloser, S. H., Woosley, R. L. (1994). Sotalol. NEJM 331: 31-38 [Full Text]  
• Damle, R. S., Ehlert, F. A., Winters, S. L., Rubinstein, D., Gomes, J. A., Mason, J. W., The ESVEM Investigators, (1994). The Treatment of Ventricular Tachyarrhythmias. NEJM 330: 286-288 [Full Text]  
• Mason, J. W., The Electrophysiologic Study versus Electrocardiog, (1993). A Comparison of Electrophysiologic Testing with Holter Monitoring to Predict Antiarrhythmic-Drug Efficacy for Ventricular Tachyarrhythmias. NEJM 329: 445-451 [Abstract] [Full Text]  
• Ward, D. E., Camm, A. J. (1993). Dangerous Ventricular Arrhythmias -- Can We Predict Drug Efficacy?. NEJM 329: 498-499 [Full Text]